All In Biotech

Drug Trial Radar · NCT07669506

A Study to Evaluate the Efficacy and Safety of Orally Administered Extract of Orthosiphon Stamineus (NuvastaticTM-C5OSEW5050ESA) in Patient With Breast Cancer Undergoing Chemotherapy

Phase III Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NuvastaticTM in Reducing Cancer-Related Fatigue in Breast Cancer Patients Undergoing Chemotherapy

Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

180

Actual

Start

Jun 17, 2025

Primary completion

Apr 25, 2026

Study completion Jun 15, 2026

Sponsor

Lead sponsor
Natureceuticals Sdn BhdIndustry
Sponsor type
Industry
First posted
Jun 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Supportive care
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to determine whether Nuvastatic™ can reduce cancer-related fatigue and improve quality of life in adult female patients with breast cancer undergoing standard chemotherapy. The main questions it aims to answer are: Does Nuvastatic™ reduce cancer-related fatigue as measured by change in the Brief Fatigue Inventory (BFI) from baseline to end of treatment? Does Nuvastatic™ improve quality of life, safety outcomes, and clinical parameters compared with placebo during chemotherapy? Researchers will compare patients receiving Nuvastatic™ plus standard chemotherapy with patients receiving placebo plus standard chemotherapy to see if Nuvastatic™ leads to greater reductions in fatigue, improved quality of life, and acceptable safety while undergoing treatment. Participants will: * Receive Nuvastatic™ or matching placebo as a 1000 mg effervescent sachet taken three times daily after meals for three chemotherapy cycles * Continue their standard-of-care chemotherapy as prescribed by their treating physician * Complete fatigue and quality-of-life questionnaires (BFI, SF-36, EORTC QLQ-C30) * Undergo routine clinical assessments, laboratory tests, ECGs, and safety monitoring * Undergo CT imaging for tumor response assessment according to RECIST 1.1

Conditions

  • Breast Neoplasms
  • Fatigue
  • Quality of Life
  • Chemotherapy, Adjuvant

Interventions

  • Nuvastatic ™Drug

    Greenhouse-sourced extract 1000mg sachet, or openfield extract 1000mg sachet

  • PlaceboDrug

    greenhouse-sourced extract 1000mg sachet, or openfield extract 1000mg sachet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Brief Fatigue Inventory (BFI) scoreTime frame: At baseline until end of treatment at 12 weeks

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Department of Medical Oncology (In Charge - Oncology Unit), Govt. Medical College & Govt. General Hospital,

    Srikakulam, Andhra Pradesh, India

  • Hanji Cancer Centre

    Belagavi, Karnataka, India

  • K.R. Hospital, Mysore Medical College & Research Institute

    Mysuru, Karnataka, India

  • Onco-Life Cancer Centre

    Satara, Maharashtra, India

  • Onco-Life Cancer Centre, Pvt. Ltd (Talegaon General Hospital)

    Talegaon Dābhāde, Maharashtra, India

  • Siddharth Gupta Memorial Cancer Hospital (A Unit of Acharya Vinoba Bhave Rural Hospital)

    Wardha, Maharashtra, India

  • Avicenna Hospital

    Lucknow, Uttar Pradesh, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.